A5100408680- Acute Myeloid Leukemia Research
- Myasthenia Gravis and Thymoma
- Advanced biosensing and bioanalysis techniques
- Cancer Genomics and Diagnostics
- Erythropoietin and Anemia Treatment
- Cardiac electrophysiology and arrhythmias
- Epigenetics and DNA Methylation
- Neuroblastoma Research and Treatments
- Antifungal resistance and susceptibility
- Ion Transport and Channel Regulation
- Peripheral Neuropathies and Disorders
- Hormonal Regulation and Hypertension
- Blood Pressure and Hypertension Studies
- Sarcoma Diagnosis and Treatment
- Heme Oxygenase-1 and Carbon Monoxide
- Adenosine and Purinergic Signaling
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Chinese Academy of Medical Sciences & Peking Union Medical College
2023
Thermo Fisher Scientific (United States)
2020-2022
Hebei Medical University
2018
Previous studies have yielded conflicting results as to whether extracellular adenosine generation and signaling contributes hypoxia-induced increases in renal erythropoietin (EPO) secretion. In this study, we combined pharmacological genetic approaches elucidate a potential contribution of EPO release mice. To stimulate secretion, used murine carbon monoxide exposure (400 750 parts per million CO, 4 h), ambient hypoxia (8% oxygen, or arterial hemodilution. Because the ecto-5-nucleotidase...
Tacrolimus is an important immunosuppressant used in the treatment of myasthenia gravis (MG). However, population pharmacokinetic (PK) characteristics together with exposure-response tacrolimus MG remain largely unknown. In this study, we aimed to develop a PK/pharmacodynamic (PK/PD) model patients MG, order explore relationships among dose, exposure, and its therapeutic efficacy. The genotype CYP3A5, Osserman's classification, status thymus, as well demographic other biomarkers from...
<p>OS and EFS for all patients enrolled PFS according to histologic group</p>
Abstract The detection of molecular measurable residual disease (MRD) for acute myeloid leukemia (AML) has shown promise as a prognostic AML. To support clinical and translational research into potential strategies MRD monitoring applications in the future, next-generation sequencing (NGS) assay, Oncomine Myeloid Assay (RUO), was developed. This assay utilizes Unique Molecular Tags (UMT) Ion AmpliSeq HD™ technology to detect ultra-low frequency genetic alterations from blood or bone marrow...